切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2026, Vol. 15 ›› Issue (03) : 263 -268. doi: 10.3877/cma.j.issn.2095-3224.2026.03.009

综述

自噬在结直肠癌发生与发展中的作用及研究进展
秦松涵, 王继伟(), 张桃, 谢铭   
  1. 563000 遵义医科大学附属医院胃肠外科 贵州省消化疾病全省重点实验室
  • 收稿日期:2025-12-01 出版日期:2026-06-25
  • 通信作者: 王继伟
  • 基金资助:
    国家自然科学基金地区科学基金项目(82560119)

The role and research progress of autophagy in the occurrence and development of colorectal cancer

Songhan Qin, Jiwei Wang(), Tao Zhang, Ming Xie   

  1. Department of Gastrointestinal Surgery, Affiliated Hospital of Zunyi Medical University, Provincial Key Laboratory of Digestive Diseases of Guizhou Province, Zunyi 563000, China
  • Received:2025-12-01 Published:2026-06-25
  • Corresponding author: Jiwei Wang
引用本文:

秦松涵, 王继伟, 张桃, 谢铭. 自噬在结直肠癌发生与发展中的作用及研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 263-268.

Songhan Qin, Jiwei Wang, Tao Zhang, Ming Xie. The role and research progress of autophagy in the occurrence and development of colorectal cancer[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2026, 15(03): 263-268.

结直肠癌是全球癌症相关死亡的第二大原因,而其发生与发展和细胞自噬(autophagy)的动态调控有复杂的联系:自噬是以溶酶体途径降解胞质成分的高度保守的自我降解过程,故在结直肠癌的发生与发展中,自噬通过调控DNA损伤修复、细胞死亡途径、细胞增殖等关键过程,实质性地影响癌细胞对结直肠癌常规疗法(化疗、放疗、免疫治疗)的反应性。因此,靶向自噬通路极有可能成为克服结直肠癌耐药性的新策略。更重要的是,现有研究证据提出:自噬在结直肠癌早期发挥抑癌作用,而在疾病进展期及药物诱导应激时转为促癌作用。基于此,本文系统总结了自噬抑制剂联合常规疗法治疗结直肠癌的潜力及优势,并据此引出其临床应用前景,也由此为优化结直肠癌治疗方案提供新的视角。

Colorectal cancer is the second leading cause of cancer-related death worldwide, and its occurrence and development are complicated by the dynamic regulation of autophagy: autophagy is a highly conserved self-degradation process that degrades cytoplasmic components through the lysosomal pathway. Therefore, in the occurrence and development of colorectal cancer, autophagy substantially affects the responsiveness of cancer cells to conventional therapies (chemotherapy, radiotherapy, immunotherapy) by regulating DNA damage repair, cell death pathway, cell proliferation and other key processes. Therefore, targeting autophagy pathway is likely to become a more powerful strategy to overcome drug resistance in colorectal cancer. More importantly, existing evidence suggests that autophagy plays a tumor suppressor role in the early stage of colorectal cancer, and then switches to a pro-tumor role during disease progression and drug-induced stress. Based on this, this paper systematically and rigorously summarizes the potential and advantages of autophagy inhibitors combined with conventional therapy in the treatment of colorectal cancer, and leads to its clinical application prospects, thereby providing a new perspective for optimizing the treatment of colorectal cancer.

图1 自噬机制(该图用figdraw绘制,作者:秦松涵)
[1]
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]
Yamamoto H, Zhang S, Mizushima N. Autophagy genes in biology and disease[J]. Nat Rev Genet, 2023, 24(6): 382-400.
[3]
Zhang T, Yu J, Cheng S, et al. Research progress on the anticancer molecular mechanism of targets regulating cell autophagy[J]. Pharmacology, 2023, 108(3): 224-237.
[4]
Jain V, Singh MP, Amaravadi RK. Recent advances in targeting autophagy in cancer[J]. Trends Pharmacol Sci, 2023, 44(5): 290-302.
[5]
Liu S, Yao S, Yang H, et al. Autophagy: regulator of cell death[J]. Cell Death Dis, 2023, 14(10): 648.
[6]
Yamamoto H, Matsui T. Molecular mechanisms of macroautophagy, microautophagy, and chaperone-mediated autophagy[J]. J Nippon Med Sch, 2024, 91(1): 2-9.
[7]
Wang L, Klionsky DJ, Shen HM. The emerging mechanisms and functions of microautophagy[J]. Nat Rev Mol Cell Biol, 2022, 24(3): 186-203.
[8]
Wang Y, Liu J, Wang H, et al. Multiple regulatory mechanisms, functions and therapeutic potential of chaperone-mediated autophagy[J]. Theranostics, 2025, 15(7): 2778-2793.
[9]
Cao W, Li J, Yang K, et al. An overview of autophagy: mechanism, regulation and research progress[J]. Bull Cancer, 2021, 108(3): 304-322.
[10]
Li Q, Geng S, Luo H, et al. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy[J]. Signal Transduct Target Ther, 2024, 9(1): 266.
[11]
Zhang Y, Li H, Lv L, et al. Autophagy: dual roles and perspective for clinical treatment of colorectal cancer[J]. Biochimie, 2023, 206: 49-60.
[12]
Garavaglia B, Vallino L, Ferraresi A, et al. Butyrate inhibits colorectal cancer cell proliferation through autophagy degradation of β-Catenin regardless of APC and β-Catenin mutational status[J]. Biomedicines, 2022, 10(5): 1131.
[13]
Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Molecular Cancer, 2022, 21(1): 144.
[14]
Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer[J]. Nat Rev Mol Cell Biol, 2023, 24(8): 560-575.
[15]
Li XL, Zhou J, Chen ZR, et al. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation[J]. World J Gastroenterol, 2015, 21(1): 84-93.
[16]
Tang J, Li Y, Xia S, et al. Sequestosome 1/p62: a multitasker in the regulation of malignant tumor aggression (Review)[J]. Int J Oncol, 2021, 59(4): 77.
[17]
Wang L, Wang Y, Lu Y, et al. Heterozygous deletion of ATG5 in Apc Min/+mice promotes intestinal adenoma growth and enhances the antitumor efficacy of interferon-gamma[J]. Cancer Biology & Therapy, 2015, 16(3): 383-391.
[18]
Li L, Jing L, Wang J, et al. Autophagic flux is essential for the downregulation of D-dopachrome tautomerase by atractylenolide I to ameliorate intestinal adenoma formation[J]. J Cell Commun Signal, 2018, 12(4): 689-698.
[19]
Leiphrakpam PD, Are C. PI3K/Akt/mTOR signaling pathway as a target for colorectal cancer treatment[J]. Int J Mol Sci, 2024, 25(6): 3178.
[20]
Tan XP, He Y, Huang YN, et al. Lomerizine 2HCl inhibits cell proliferation and induces protective autophagy in colorectal cancer via the PI3K/Akt/mTOR signaling pathway[J]. MedComm (2020), 2021, 2(3): 453-466.
[21]
Li JK, Sun HT, Jiang XL, et al. Polyphyllin Ⅱ induces protective autophagy and apoptosis via inhibiting PI3K/AKT/mTOR and STAT3 signaling in colorectal cancer cells[J]. Int J Mol Sci, 2022, 23(19): 11890.
[22]
Li Y, Yan W, Qin Y, et al. The anthraquinone derivative C2 enhances oxaliplatin-induced cell death and triggers autophagy via the PI3K/AKT/mTOR pathway[J]. Int J Mol Sci, 2024, 25(12): 6468.
[23]
Wang S, Li H, Yuan M, et al. Role of AMPK in autophagy[J]. Frontiers in Physiology, 2022, 13: 1015500.
[24]
Yuan W, Fang W, Zhang R, et al. Therapeutic strategies targeting AMPK-dependent autophagy in cancer cells[J]. Biochim Biophys Acta Mol Cell Res, 2023, 1870(7): 119537.
[25]
Xiang X, Tian Y, Hu J, et al. Fangchinoline exerts anticancer effects on colorectal cancer by inducing autophagy via regulation AMPK/mTOR/ULK1 pathway[J]. Biochem Pharmacol, 2021, 186: 114475.
[26]
Yu H, Huang Y, Ge Y, et al. Selenite-induced ROS/AMPK/FoxO3a/GABARAPL-1 signaling pathway modulates autophagy that antagonize apoptosis in colorectal cancer cells[J]. Discov Oncol, 2021, 12(1): 35.
[27]
Athamneh K, Alneyadi A, Alsamri H, et al. Origanum majorana Essential oil triggers p38 MAPK-mediated protective autophagy, apoptosis, and caspase-dependent cleavage of P70S6K in colorectal cancer cells[J]. Biomolecules, 2020, 10(3): 412.
[28]
Han SH, Lee JH, Woo JS, et al. Platycodin D induces apoptosis via regulating MAPK pathway and promotes autophagy in colon cancer cell[J]. Biomed Pharmacother, 2024, 172: 116216.
[29]
Gamage CDB, Kim JH, Yang Y, et al. Libertellenone T, a novel compound isolated from endolichenic fungus, induces G2/M phase arrest, apoptosis, and autophagy by activating the ROS/JNK pathway in colorectal cancer cells[J]. Cancers (Basel), 2023, 15(2): 489.
[30]
Li T, Li T, Zhang H, et al. Maintenance of the expression of c-FLIPL by Hsp70 to resist licochalcone a-induced anti-colorectal cancer effect through ERK-mediated autophagy induction[J]. Front Biosci (Landmark Ed), 2023, 28(12): 325.
[31]
Manzoor S, Muhammad JS, Maghazachi AA, et al. Autophagy: a versatile player in the progression of colorectal cancer and drug resistance[J]. Front Oncol, 2022, 12: 924290.
[32]
Yamamoto K, Iwadate D, Naito E, et al. Autophagy as a critical driver of metabolic adaptation, therapeutic resistance, and immune evasion of cancer[J]. Curr Opin Biotechnol, 2023, 84: 103012.
[33]
Xing F, Liu N, Wang C, et al. Caffeic acid phenethyl ester promotes oxaliplatin sensitization in colon cancer by inhibiting autophagy[J]. Sci Rep, 2024, 14(1): 14624.
[34]
Feng Z, Zhang S, Han Q, et al. Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1α to inhibit autophagy[J]. Phytomedicine, 2024, 129: 155647.
[35]
Yu K, Pu H, Zhang X, et al. CLMP increases 5-fluorouracil sensitivity in colorectal cancer through the inhibition of autophagy[J]. Tissue Cell, 2025, 93: 102771.
[36]
Tessmann JW, Rocha MR, Morgado-Díaz JA. Mechanisms of radioresistance and the underlying signaling pathways in colorectal cancer cells[J]. J Cell Biochem, 2023, 124(1): 31-45.
[37]
Chaaya C, Zgheib G, El Karak F. Pharmacotherapy developments in autophagy inhibitors for bladder cancer[J]. Expert Opin Pharmacother, 2023, 24(17): 1853-1860.
[38]
Yazal T, Bailleul J, Ruan Y, et al. Radiosensitizing pancreatic cancer via effective autophagy inhibition[J]. Mol Cancer Ther, 2022, 21(1): 79-88.
[39]
Jiang T, Chen X, Ren X, et al. Emerging role of autophagy in anti-tumor immunity: implications for the modulation of immunotherapy resistance[J]. Drug Resist Updat, 2021, 56: 100752.
[40]
Zhang W, Chen L, Liu J, et al. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer[J]. J Exp Clin Cancer Res, 2024, 43(1): 114.
[41]
Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-Ⅰ[J]. Nature, 2020, 581(7806): 100-105.
[1] 佘欣怡, 万玮祺, 刘广健, 黄玉笑, 胡金枝, 覃斯. 超声造影定量评估结直肠癌化疗后肝窦阻塞综合征的前瞻性临床研究[J/OL]. 中华医学超声杂志(电子版), 2026, 23(02): 151-161.
[2] 崔梦玲, 孙文梅, 赵睿敏, 王家平. 合并微血管侵犯肝癌术后TACE联合治疗的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(02): 160-166.
[3] 王浩, 辛才进, 崔静, 傅鹤鑫, 朱长仁, 汪刘华. 错配修复蛋白在早发性结直肠癌中的表达及意义[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 209-214.
[4] 孟春孜, 章群, 钱晓萍. 晚期结直肠癌三线免疫联合方案与单药化疗或单药靶向治疗的疗效对比Meta分析[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 215-223.
[5] 贾宇飞, 王哲学, 王飞, 蔡昂书, 姚占胜. 中性粒细胞与淋巴细胞比值(NLR)和结直肠癌幸存者全因死亡的关联研究:基于NHANES 1999—2018数据的分析[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 224-231.
[6] 王利明, 马浩越, 余永刚, 陈瑛罡. 结直肠癌手术切除范围的理论依据[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 115-121.
[7] 张雨霄, 潘怡, 邱田, 邹霜梅. 行二代测序结直肠癌患者cMET的表达水平与临床病理特征和分子特征的相关性及预后价值的研究[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 122-132.
[8] 温钰, 张尊庶, 丁泽浩, 郑仁杰, 武宾, 孙海翔, 韩超, 黄陈. 基于淋巴结转移的结直肠癌新分期与预后关系[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 133-145.
[9] 王欢, 王伟彪, 李多, 于永强, 武雪亮, 樊建春. 基于溶酶体相关基因构建结直肠癌预后模型的研究[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 146-159.
[10] 张钧, 梁宗康, 高天, 闫泽宇, 王刚, 高鹏, 何显力. SEMS植入后序贯新辅助治疗与腹腔镜手术在梗阻性结直肠癌中的应用效果对比:一项倾向评分匹配研究[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 160-167.
[11] 张逸辰, 冯雨舟, 鲍传庆. PROTAC在结直肠癌肿瘤微环境治疗中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 175-180.
[12] 张婧萱, 郭佳星, 李紫红, 陈怡颖, 乔媛, 宝莹娜. 多线治疗失败后31例复发转移性结直肠癌局部挽救性放射治疗的研究[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(03): 206-211.
[13] 梁玮龙, 王鹏飞, 高怀新. 氟比洛芬酯联合腹横肌平面阻滞在腹腔镜结直肠癌根治术中的麻醉效果及对COX-2、MMP-9水平的影响[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(03): 256-261.
[14] 倪玮峰, 田文扬, 倪雨玲, 杨海宁, 施岳柱. 脂质代谢在七氟烷与丙泊酚麻醉对老年结直肠癌患者认知功能中的作用[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(02): 173-178.
[15] 印于, 俞斌, 冯文聪, 杨俊, 倪才方, 朱晓黎, 李智, 李明明. 动脉化疗栓塞联合锥形束断层扫描引导乙醇注射治疗危险部位小肝癌的疗效与安全性[J/OL]. 中华介入放射学电子杂志, 2026, 14(02): 157-163.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?